anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli, the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium brevis, or Enterobacter cloacae. The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. Further embodiments provide compositions comprising arsinothricin or a salt thereof and an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.
The study is conducted as an open-label, single-arm, two-period, crossover pilot trial. Includible patients are observed for 5 weeks on their usual treatment (twice or thrice daily hydrocortisone). Assessments of QoL, in terms of EMA assessments, to be used as baseline measurement in the study, are collected for 20 days preceded by a 5 days technology adaptation phase. Thereafter participants are shifted to modified release hydrocortisone (Plenadren) once daily (OD), on a dose as per Summary of Product Characteristics (SmPC). Assessments of QoL to be used as outcome of intervention in the study are performed after 12.5 weeks after initiation of Plenadren intervention treatment, in order to take into consideration the period of re-adjustment of the body after the switch from conventional hydrocortisone to Plenadren. As done at the baseline observation, EMA measurement is preceded by a five days technology adaptation phase. At the end of the intervention treatment period, the patients will be shifted to their usual hydrocortisone treatment and will be followed at the outpatient clinic according to the directives of the clinic. Biochemical parameters; blood samples, DEXA scan, 24 hour blood pressure and salivary cortisol, will be assessed at baseline and after 16 weeks, as part of the safety evaluation of Plenadren.
Eleven male middle-aged participants will be included in this study. Participants will be initially informed about the main goals of study as well as the associated risks and benefits and then will provide their signed consent form. At baseline, they will undergo assessment of their anthropometrics (body mass, height, BMI, WHR), body compotition (using DXA), physical contition level (peak oxygen consumption, VO2peak), haemodynamic profile (diastolic and diastolic blood pressure) and daily dietary intake.Thereafter, they will participate in two experimental trials (Control trial and Soccer trial) in a randomized, crossover, repeated measure design: 1) ST (Soccer Trial): Participants in this trial will perform a soccer training session (60 min) consisted of warm-up, technical exercises and small-sided game, CT (Control Trial): Participants in this trial will only execute the evaluations daily in the dependent variables (they will not receive any intervention). Before each trial, the participants will provide a resting blood sample (for the determination of white blood cells, granulocyte cells, monocyte cells, lymphocyte cells, Hemeatocrit, Hemoglobin, red blood cells and platelets, total antioxidant capacity, glutathione and creatine kinase activity) and undergo assessments of their delay onset muscle soreness (DOMS), maximal voluntary isometric contraction (MVIC) of knee extensors and flexors (by isokinetic dynamometer), height and power of countermovement jump (CMJ-using force platform), 10m and 30m sprint time (will be evaluated using light cells). A 7-day wash-out period will apllied between ST and CT. The blood sample will be collected before and 24, 48 and 72 hours post-taining. Also, the evaluation of DOMS, MVIC, sprinting performance, power and jump height (by CMJ) will be evaluated before and 24, 48, 72 and 96 hours post training.
PURPOSE:An oral band, capable of removing tobacco tar readily on application to a tooth, and comprising a drying base consisting of a high polymer exhibiting tackiness in the presence of water mainly and phytic acid or a derivative thereof. CONSTITUTION:An oral band comprising (A) a drying base consisting of a high polymer which exhibits tackiness on dissolution in or gelation with water mainly and (B) phytic acid (myo-inositol hexaphosphate) or a derivative thereof. For example, the base (A) and active constituent (B) are mixed with water and freeze- dried to form the oral band for removing tobacco tar in the form of a sponge. In use, the band is applied and attached immediately to a tooth with saliva firmly for a long time. The acid (B) acts for a long time to swell and scale the tar from the tooth etc. Thus, the tar which has not been easily eliminated in the past can be removed readily without damaging the tooth.
A physiological signal monitoring system includes a single set of sensing electrodes to provide conditioned physiological signals to a primary monitoring device and a secondary monitoring device. The monitoring system includes pre-processing circuitry configured to receive a raw physiological signal. The pre-processing circuitry is configured to produce a primary physiological signal and a secondary physiological signal. Each of the primary and secondary physiological signals are conditioned. The primary conditioned physiological signal is directed to a primary monitoring device such as a hospital wearable defibrillator device. The secondary conditioned physiological signal is directed to telemetry modeling circuitry where it is further processed to output one or more telemetry signals. The one or more telemetry signals are output to a secondary monitoring device such as a three lead ECG monitoring device. Thus, a single set of sensing electrodes can provide physiological signals to multiple monitoring devices.
The invention concerns variants of recombinant human interferon- gamma  (rhu-IFN- gamma ) having increased heat-stability. Proceeding from rhu-IFN- gamma , at least one of the following amino acid pairs is changed into cysteine in the amino acid sequence of the polypeptide monomer: Glu8 and Ser70, Ala18 and His112, Lys81 and Leu121, and Gln49 and Leu96. Additionally, the C-terminal end of the polypeptide can be shortened by between 1 and 10 amino acids. The novel proteins according to the invention have greater heat-stability than the unchanged rhu-IFN- gamma  without any loss in biological activity. The invention further concerns the preparation of the oligonucleotides, vectors and micro-organisms necessary for producing the proteins according to the invention. Finally, the invention concerns a process for the preparation of the proteins and uses thereof.
<P>PROBLEM TO BE SOLVED: To efficiently collect multiple images.  <P>SOLUTION: A storage management section 26 creates creation method data indicating a creation method of secondary data. The creation method data are stored in a storage section 25. The storage management section 26, in response to the necessity of the reading of the secondary data for displaying the secondary image or the like, determines the creation method of the secondary data, or the object of reading, based on the creation method data stored in the storage section 25 and requests the secondary data creation section 23 to create the secondary data based on the creation method. The storage management section 26 reads the image data created by the secondary data creation section 23 in response to the request of the creation and outputs as the data.  <P>COPYRIGHT: (C)2007,JPO&INPIT
BACKGROUND: The intricacies of nucleotide metabolism within tumor cells specific to colorectal cancer (CRC) remain insufficiently characterized. A nuanced examination of particular tumor clusters and their dynamic interplay with the tumor microenvironment (TME) may yield profound insights into these therapeutically auspicious communicative networks.
METHODS: By integrating ten types of single-cell enrichment scoring methods, we carried out enrichment analysis on CRC cell types, which was validated through four additional single-cell cohorts. Groups of tumor cells were determined using the average values of the scores. Using cellphonedb, monocle, inferCNV, SCENIC, and Cytotrace, functional analyses were performed. Utilizing the RCTD approach, single-cell groupings were mapped onto spatial transcriptomics, analyzing cell dependency and pathway activity to distinguish between tumor cell subtypes. Differential expression analysis identified core genes in nucleotide metabolism, with single-cell and spatial transcriptomics analyses elucidating the function of these genes in tumor cells and the immune microenvironment. Prognostic models were developed from bulk transcriptome cohorts to forecast responses to immune therapy. Laboratory experiments were conducted to verify the biological function of the core gene.
RESULTS: Nucleotide metabolism is significantly elevated in tumor cells, dividing them into two groups: NUhighepi and NUlowepi. The phenotype NUhighepi was discerned to exhibit pronounced malignant attributes. Utilizing the analytical tool stlearn for cell-to-cell communication assessment, it was ascertained that NUhighepi engages in intimate interactions with fibroblasts. Corroborating this observation, spatial transcriptome cell interaction assessment through MISTy unveiled a particular reliance of NUhighepi on fibroblasts. Subsequently, we pinpointed NME1, a key gene in nucleotide metabolism, affirming its role in thwarting metastasis via in vitro examination. Utilizing multiple machine learning algorithms, a stable prognostic model (NRS) has been developed, capable of predicting survival and responses to immune therapy. In addition, targeted drugs have been identified for both high and low scoring groups. Laboratory experiments have revealed that NME1 can inhibit the proliferation and invasion of CRC tumor cells.
CONCLUSION: Our study elucidates the potential pro-tumor mechanism of NUhighepi and the role of NME1 in inhibiting metastasis, further deepening the understanding of the role of nucleotide metabolism in colorectal cancer, and providing valuable targets for disrupting its properties.
INTRODUCTION/AIMS: The precise relationship between molecular mimicry and tissue-specific autoimmunity is unknown. Major histocompatibility complex (MHC) class II antigen presenting cell-CD4+ T-cell receptor complex interactions are necessary for adaptive immunity. This study aimed to determine the role of endoneurial endothelial cell MHC class II in autoimmune polyneuropathy.
METHODS: Cryopreserved Guillain-Barré syndrome (GBS) patient sural nerve biopsies and sciatic nerves from the severe murine experimental autoimmune neuritis (sm-EAN) GBS model were studied. Cultured conditional ready MHC Class II antigen A-alpha chain (H2-Aa) embryonic stem cells were used to generate H2-Aaflox/+ C57BL/6 mice. Mice were backcrossed and intercrossed to the SJL background to generate H2-Aaflox/flox SJL mice, bred with hemizygous Tamoxifen-inducible von Willebrand factor Cre recombinase (vWF-iCre/+) SJL mice to generate H2-Aaflox/flox; vWF-iCre/+ mice to study microvascular endothelial cell adaptive immune responses. Sm-EAN was induced in Tamoxifen-treated H2-Aaflox/flox; vWF-iCre/+, H2-Aaflox/flox; +/+, H2-Aa+/+; vWF-iCre/+ and untreated H2-Aaflox/flox; vWF-iCre/+ adult female SJL mice. Neurobehavioral, electrophysiological and histopathological assessments were performed at predefined time points.
RESULTS: Endoneurial endothelial cell MHC class II expression was observed in normal and inflamed human and mouse peripheral nerves. Tamoxifen-treated H2-Aaflox/flox; vWF-iCre/+ mice were resistant to sm-EAN despite extensive MHC class II expression in lymphoid and non-lymphoid tissues.
DISCUSSION: A conditional MHC class II knockout mouse to study cell- and time-dependent adaptive immune responses in vivo was developed. Initial studies show microvascular endothelial cell MHC class II expression is necessary for peripheral nerve specific autoimmunity, as advocated by human in vitro adaptive immunity and ex vivo transplant rejection studies.
New cpds. of formula : (where X is O or NH; A is a branched or linear divalent alkyl or >6C; R is amino aliphatic gp. or 5,6 or 7-membered N-heterocycle, opt. including a second heteroatom chosen from O, S and N), and their acid addn. salts, are prepd. by condensing trimethoxy-2,4,6-benzoic acid to the chloric acid with HXAR. - Used as antispasmodics and for digestive troubles.
BACKGROUND: Neglected tropical diseases (NTDs) affect millions of people in Africa, with Uganda bearing a significant burden. The World Health Organization (WHO) set a goal to reduce NTDs and improve access to diagnosis and management by 2030. However, NTDs have not been well integrated into primary healthcare in many countries, including Uganda, due to limited knowledge and resources among health workers. The study aimed to assess the readiness and capacity of primary healthcare centres to diagnose and manage soil-transmitted helminths (STHs) and schistosomiasis.
METHODS: A cross-sectional quantitative study was conducted among 204 health workers in 20 health facilities in four districts bordering Lake Kyoga. In this study we evaluated health workers' knowledge of symptoms, diagnosis and management of STHs and schistosomiasis as well as the availability of resources and training.
RESULTS: Our findings indicate that health workers have strong knowledge about STHs (86.76%), with lower knowledge levels regarding Schistosoma haematobium (59.72%) and Schistosoma mansoni (71.43%). Regarding resources and training, 95% of health facilities had laboratory services, but the majority lacked diagnostic equipment. Furthermore, only 17% of health workers reported prior training on schistosomiasis and related topics and only 25% had training on surveillance and reporting.
CONCLUSIONS: While health workers in eastern Uganda demonstrated a good knowledge base for some NTDs, there were knowledge gaps and challenges in training on surveillance and reporting mechanisms. Continuously building the capacity of health workers along with investing in diagnostic infrastructure is essential for improved NTD control and ultimately reducing associated morbidity and mortality in the region.
Methods and apparatus for providing rule-based access to data stored on wearable devices are provided. A wearable computing device can store data that includes data about a wearer of the wearable computing device. The wearable computing device can receive a request for a portion of the stored data. The wearable computing device can determine a designated role associated with the request for the portion of the stored data. The wearable computing device can determine one or more rules regarding access to the portion of the stored data based on the designated role. The wearable computing device can determine a response to the request for the portion of the stored data by at least: determining whether the request is validated by at least applying the one or more rules to the request, and after determining that the request is validated, providing the requested portion of the stored data.
The invention discloses a fusion protein PP19128R and application thereof in preventing or treating mycobacterium tuberculosis infection. Specifically disclosed are fusion proteins comprising HTL, CTL and B cell epitopes, porB, RS-09 and PADRE in tandem. The invention screens 39 epitopes aiming at mycobacterium tuberculosis, has good immunogenicity and antigenicity, is nontoxic and non-sensitized, and has the characteristics of high population coverage rate and the like. The auxiliary peptide PADRE is further added to improve the immunogenicity of the vaccine, and PorB and RS-09 are added to endow the vaccine with a targeted delivery function. In vitro experiments prove that the PP19128R can stimulate human peripheral blood mononuclear cells to generate immune response, and is an advantageous protective antigen. The PP19128R as a vaccine has the advantages of simple preparation method, low cost, high yield, safety and the like. The invention has great value for epidemic prevention and treatment of active tuberculosis and tuberculosis latent infection.
Participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) will receive 9 μg/kg/day of E7777, administered by intravenous drip infusion in 60 minutes (± 10 min) for Days 1 through 5 of each cycle in maximum of 8 cycles. Every cycle consists of 3 weeks.
Idiopathic pulmonary artery hypertension (IPAH) is a rare but progressive disease in children and adults with a very high mortality from right heart failure. Platelet derived growth factor (PDGF) has been implicated in the pulmonary artery remodeling and vascular proliferation that is a pathologic hallmark of IPAH. Animal and clinical data support the hypothesis that activation of the PDGF receptor is critical in the development of IPAH, and inhibition of the PDGF signaling pathways may be a potential therapeutic target. Gleevec is a tyrosine kinase inhibitor developed for treatment of certain cancers and inhibits the PDGF receptor. Animal and preliminary clinical data suggest that Gleevec can reverse vascular remodeling and improve right heart failure. A small clinical trial for adults with IPAH is ongoing in Europe, but there are no trials in children where the disease has a worse prognosis. This project is a phase II, single dose pilot study to generate the hypothesis that activation of the PDGF receptor is critical in the development of IPAH, and inhibition of the PDGF signaling pathways is a potential therapeutic target. Five patients between the ages of 8 yr to 18 yr with severe IPAH will be recruited nationally, for a 6 month trial of Imatinib. The Specific Aim of this study is to collect preliminary data on the safety and efficacy of Gleevec in children with IPAH. Results from this study are needed to develop a larger, multi-center trial to determine the efficacy and therapeutic impact of Gleevec in children with IPAH. The long term goal of this work is to develop novel therapeutic strategies for treatment of IPAH in children. This translational study of the inhibition of the PDGF receptor in children with IPAH could provide insights into the etiology of IPAH and have a major impact on the development of new treatment strategies for both children and adults with pulmonary artery hypertension from multiple origins.
A total of 82 Participants will be assigned to experimental group. Transformational educational programme is administered to all the participants.
PURPOSE: To compare the audiological outcomes, tympanic membrane (TM) healing rates and complication rates in patients undergoing endoscopic underlay and over-under tympanoplasty type I (TTI).
METHODS: The study includes 95 patients who underwent endoscopic TTI in the period between 2018 and 2023: 56% of the patients had the underlay technique and 41% had the over-under technique. Data regarding pre- and postoperative hearing, perforation characteristics, surgical procedures, graft types and complications were retrospectively analyzed. Audiometrical assessment included air conduction (AC) and bone conduction (BC) pure tone averages (PTA) and air-bone gap (ABG), pre- and postoperatively.
RESULTS: Both underlay and over-under techniques significant improved AC PTA, with a mean ABG improvements of 5.9 dB and 7.2 dB, respectively. There was no significant difference in BC PTA between pre- and post-operative, indicating no inner ear damage in both techniques. The over-under technique showed a significantly higher TM closure rate (94.4%) compared to the underlay technique (80.6%). Complications were rare, with only one case of TM lateralization requiring revision surgery.
CONCLUSIONS: Endoscopic TTI is an effective treatment in improving auditory function in chronic middle ear diseases. In our cohort, the detachment of the umbo does not negatively influence the postoperative hearing results and does not increase rate of complications. Moreover, the over-under technique demonstrates superior TM closure rates, making it a valuable option for specific cases. However, future prospective studies with larger sample sizes and longer term follow-up are needed to validate these findings and provide more comprehensive insights.
Disclosed are compositions and methods related to clot binding compounds. For example, disclosed are conjugates comprising a surface molecule and a plurality of clot binding compounds. The clot binding compounds can selectively bind to clotted plasma protein. The conjugate can, for example, cause clotting and amplify the accumulation of the conjugate in tumors. In one example, the conjugate can comprise a sufficient number and composition of clot binding compounds such that the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
Kinesiotape (KT) is a technique commonly used in sports practice. It may be beneficial in enhancing muscle function by additional cutaneous afferent stimulation. The objective of this study was to analyze the effect of KT on countermovement jump (CMJ) and 20-m sprints immediately and 24 hours after its application on the quadriceps and gluteus maximus. A total of 37 male soccer players (19.7 ± 0.9 years old) were randomly assigned to one of 3 groups: experimental group: KT activation (KTact), placebo group: sham tape (KTst), and control group (CG). Participants performed a 30-minute preliminary warm-up, after which they conducted CMJ and 20-m sprint tests. These tests were repeated later (with KT application or not) and after 24 hours.
Immune deficiency and viral infection is of great concern throughout the world. Immune deficiency is due to a failure of the body's immune system, which normally protects the body against infecting organisms and, for instance, the development of cancer. AIDS (acquired immune deficiency syndrome) and other immune deficiency disorders increase susceptibility to certain type of diseases, cancer and recurrent or persistent infections. The invention suggests a novel pharmaceutical preparation for treating viral infections and which also can be utilized as an immune stimulant. According to the invention a pharmaceutical preparation for treating viral infections includes a powder or an extract derived from Vernonia Oligocephalus plant species, particularly from aerial parts. 8  a  -(2-hydroxymethyl acryloyloxy)-hirsutinolide-13-0-acetate may be the extract derived from the Vernonia Oligocephalus plant species.
FIELD: pharmacologically active substances. SUBSTANCE: method of isolating a new substance from human and animal gastric juice includes following purification steps: centrifugation, dialysis, ion-exchange, and lyophilization. Invention also provides a drug to be applied in medicine and veterinary and a method for its utilization when treating diseases and disturbances induced by stress effects, inflammation processes, edemas, diseases and disturbances with dopamine-ergic etiology, sugar disease, diseases and disturbances of functions of digestive tract organs, heart, kidneys, pancreas, liver, male genital glands, blood-generating organs, skeleton and nervous system, senile mental deficiency, wounds, burns, fractures, viral diseases, malignant neoplasms, in surgical practice, some disturbances of reproductive function and immune system. Substance is efficient in protecting against ionizing radiation and is apt to be applied in commercial stock-raising. EFFECT: enhanced therapeutic effect. 3 cl